PortfoliosLab logoPortfoliosLab logo
IPH.PA vs. CRI.PA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IPH.PA vs. CRI.PA - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Innate Pharma (IPH.PA) and Chargeurs S.A. (CRI.PA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IPH.PA achieves a -3.00% return, which is significantly higher than CRI.PA's -16.12% return. Over the past 10 years, IPH.PA has underperformed CRI.PA with an annualized return of -18.95%, while CRI.PA has yielded a comparatively higher 1.54% annualized return.


IPH.PA

1D
0.91%
1M
22.56%
YTD
-3.00%
6M
-7.06%
1Y
-18.89%
3Y*
-18.21%
5Y*
-12.39%
10Y*
-18.95%

CRI.PA

1D
-0.59%
1M
-1.41%
YTD
-16.12%
6M
-17.36%
1Y
-23.55%
3Y*
-12.62%
5Y*
-16.06%
10Y*
1.54%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IPH.PA vs. CRI.PA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
IPH.PA
Innate Pharma
-3.00%-17.08%-26.26%-20.36%-26.03%28.48%-41.91%-19.84%56.53%-67.49%
CRI.PA
Chargeurs S.A.
-16.12%2.39%-15.41%-13.92%-42.80%57.43%4.57%6.36%-30.83%62.69%

Correlation

The correlation between IPH.PA and CRI.PA is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Nov 2, 2006

0.21

The correlation between IPH.PA and CRI.PA shifts across timeframes, from 0.12 (1 year) to 0.24 (5 years), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Innate Pharma

Chargeurs S.A.

Return for Risk

IPH.PA vs. CRI.PA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IPH.PA
IPH.PA Risk / Return Rank: 2828
Overall Rank
IPH.PA Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
IPH.PA Sortino Ratio Rank: 3030
Sortino Ratio Rank
IPH.PA Omega Ratio Rank: 3030
Omega Ratio Rank
IPH.PA Calmar Ratio Rank: 2828
Calmar Ratio Rank
IPH.PA Martin Ratio Rank: 2626
Martin Ratio Rank

CRI.PA
CRI.PA Risk / Return Rank: 88
Overall Rank
CRI.PA Sharpe Ratio Rank: 66
Sharpe Ratio Rank
CRI.PA Sortino Ratio Rank: 88
Sortino Ratio Rank
CRI.PA Omega Ratio Rank: 88
Omega Ratio Rank
CRI.PA Calmar Ratio Rank: 1111
Calmar Ratio Rank
CRI.PA Martin Ratio Rank: 77
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IPH.PA vs. CRI.PA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Innate Pharma (IPH.PA) and Chargeurs S.A. (CRI.PA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IPH.PACRI.PADifference
Sharpe ratioReturn per unit of total volatility

+0.64

Sortino ratioReturn per unit of downside risk

+1.27

Omega ratioGain probability vs. loss probability

1.00

0.84

+0.16

Calmar ratioReturn relative to maximum drawdown

-0.41

-0.80

+0.40

Martin ratioReturn relative to average drawdown

-0.81

-1.46

+0.65

IPH.PA vs. CRI.PA - Sharpe Ratio Comparison

The current IPH.PA Sharpe Ratio is -0.29, which is higher than the CRI.PA Sharpe Ratio of -0.93. The chart below compares the historical Sharpe Ratios of IPH.PA and CRI.PA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IPH.PACRI.PADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.29

-0.93

+0.64

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.20

-0.44

+0.23

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.33

0.04

-0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.10

-0.03

-0.07

Drawdowns

IPH.PA vs. CRI.PA - Drawdown Comparison

The maximum IPH.PA drawdown since its inception was -93.57%, roughly equal to the maximum CRI.PA drawdown of -92.33%. Use the drawdown chart below to compare losses from any high point for IPH.PA and CRI.PA.


Loading charts...

Drawdown Indicators


IPH.PACRI.PADifference

Max Drawdown

Largest peak-to-trough decline

-93.57%

-92.33%

-1.24%

Max Drawdown (1Y)

Largest decline over 1 year

-47.59%

-29.70%

-17.89%

Max Drawdown (3Y)

Largest decline over 3 years

-67.61%

-49.29%

-18.32%

Max Drawdown (5Y)

Largest decline over 5 years

-84.91%

-75.71%

-9.20%

Max Drawdown (10Y)

Largest decline over 10 years

-93.22%

-75.71%

-17.51%

Current Drawdown

Current decline from peak

-90.54%

-67.79%

-22.75%

Average Drawdown

Average peak-to-trough decline

-63.73%

-49.90%

-13.83%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.53%

16.44%

+7.09%

Volatility

IPH.PA vs. CRI.PA - Volatility Comparison

Innate Pharma (IPH.PA) has a higher volatility of 38.44% compared to Chargeurs S.A. (CRI.PA) at 5.47%. This indicates that IPH.PA's price experiences larger fluctuations and is considered to be riskier than CRI.PA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IPH.PACRI.PADifference

Volatility (1M)

Calculated over the trailing 1-month period

38.44%

5.47%

+32.97%

Volatility (6M)

Calculated over the trailing 6-month period

49.91%

16.90%

+33.01%

Volatility (1Y)

Calculated over the trailing 1-year period

65.73%

25.60%

+40.13%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

59.89%

36.08%

+23.81%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

55.98%

38.35%

+17.63%

Dividends

IPH.PA vs. CRI.PA - Dividend Comparison

IPH.PA has not paid dividends to shareholders, while CRI.PA's dividend yield for the trailing twelve months is around 1.55%.


PositionTTM20252024202320222021202020192018201720162015
CRI.PA
Chargeurs S.A.
1.55%1.30%0.00%4.62%6.96%5.83%2.73%3.30%5.95%2.37%3.13%2.22%
IPH.PA
Innate Pharma
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

IPH.PA vs. CRI.PA - Financials Comparison

This section allows you to compare key financial metrics between Innate Pharma and Chargeurs S.A.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in EUR except per share items

Frequently Asked Questions


IPH.PA and CRI.PA have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for IPH.PA and CRI.PA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer